Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Advanced BiomedADVB +76.94%12 Equity-to-Asset is 0.87 as of Mar. 2026, which is 78% above its 10-year median of 0.49. GuruFocus rates ADVB with a GF Score™ of 12/100. The stock has 1 warning sign investors should review. Among 212 Medical Diagnostics & Research companies, Advanced Biomed ranks better than 91.51% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Advanced Biomed's Total Stockholders Equity for the quarter that ended in Mar. 2026 was $9.21 Mil. Advanced Biomed's Total Assets for the quarter that ended in Mar. 2026 was $10.65 Mil.
The historical rank and industry rank for Advanced Biomed's Equity-to-Asset or its related term are showing as below:
ADVB'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.04 Med: 0.49 Max: 0.97
Current: 0.87
During the past 5 years, the highest Equity to Asset Ratio of Advanced Biomed was 0.97. The lowest was 0.04. And the median was 0.49.
ADVB's Equity-to-Asset is ranked better than 91.51% of 212
companies
in the Medical Diagnostics & Research industry
Industry Median: 0.59
vs ADVB: 0.87
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Advanced Biomed Equity-to-Asset Related Terms
Advanced Biomed Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Advanced Biomed's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ADVB vs MBAI, XWEL, NDRA: Equity-to-Asset Comparison
For the Diagnostics & Research subindustry, Advanced Biomed's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Advanced Biomed Equity-to-Asset vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Advanced Biomed's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Advanced Biomed's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Advanced Biomed's Equity to Asset Ratio for the fiscal year that ended in Jun. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Advanced Biomed (ADVB) has a Equity-to-Asset of 0.87 as of Mar. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Advanced Biomed and its competitors. This is 78% above median its historical median of 0.49. Over the past decade, Advanced Biomed's Equity-to-Asset has ranged from 0.04 to 0.97. According to the industry distribution chart, Advanced Biomed ranks #18 out of 212 companies in the Medical Diagnostics & Research industry, placing it in the top 8.5%.
Is Advanced Biomed's Equity-to-Asset too high?
Advanced Biomed's current Equity-to-Asset of 0.87 is 78% above median its 10-year median of 0.49. Over the past 10 years, this metric has ranged from a low of 0.04 to a high of 0.97. The Medical Diagnostics & Research industry median Equity-to-Asset is 0.59. Advanced Biomed's value of 0.87 is 47.5% above this industry median. Based on the distribution chart, Advanced Biomed ranks #18 out of 212 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Advanced Biomed has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Advanced Biomed's Equity-to-Asset compare to MBAI and XWEL?
According to the Medical Diagnostics & Research industry distribution chart, Advanced Biomed ranks #18 out of 212 companies for Equity-to-Asset. This places Advanced Biomed in the top 9% of its industry — outperforming the majority of peers. The industry median Equity-to-Asset is 0.59. Advanced Biomed's value of 0.87 is 47.5% above this benchmark. Historically, Advanced Biomed's own Equity-to-Asset has ranged from 0.04 to 0.97 over the past decade. While the company's 10-year median is 0.49 vs. the industry median of 0.59, Advanced Biomed has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Medical Diagnostics & Research company?
The median Equity-to-Asset among Medical Diagnostics & Research companies is 0.59, based on 212 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Advanced Biomed's current Equity-to-Asset of 0.87 is 47.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Advanced Biomed and its competitors. For the Medical Diagnostics & Research industry, the median Equity-to-Asset is 0.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Advanced Biomed's current Equity-to-Asset is 0.87, which is 78% above median its own 10-year median of 0.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Advanced Biomed stock overvalued right now?
Advanced Biomed (ADVB) has a current Equity-to-Asset of 0.87. The current Equity-to-Asset is 0.87, which is 78% above median its 10-year median of 0.49 and 47.5% above the Medical Diagnostics & Research industry median of 0.59. Advanced Biomed's overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Advanced Biomed (ADVB), the current Equity-to-Asset is 0.87 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Advanced Biomed Inc operates through its subsidiaries and is mainly engaged in the research and development of various original microfluidic biochip technologies and the provision of tumor precision diagnosis and treatment technology applications. Through the joint application of semiconductor technology and biotechnology, it has developed various technologies and testing equipment for early screening and detection, diagnosis and staging, and treatment of cancer. Its devices: A+Pre, AC-1000, A+CellScan, and A+SCDrop, and three corresponding microfluidic biochips, A+Pre Chip and AC-1000 CTC Enrichment Chip, and A+CellScan Chip, are designed to provide rapid and affordable assay products and services to cancer patients.
12GF Score
Get the complete analysis for ADVB
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ADVB has been successfully added to your 
